The outline of initial findings by Dr Mondello relates to the first cohort of the Phase II Intrepid2566 trial. Enrolment for the first cohort, however, was completed in May 2011. Its fascinating why the findings are being presented at this stage. Would it really take more than two years to analyse the data?
Perhaps it's been a work in progress?? Do you think it may also have something to do with evaluating the drug's possible molecular mechanisms? Note re outline, the markers are also being evaluated to identify possible molecular mechanisms of the drug. I found this fascinating.
Also have another read of the Arrowhead presentation...
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)